Search in:

Advanced search

Clinical Ophthalmology Volume 10, 2016 - Issue

Submit an article Journal homepage

Open access

207

Views

CrossRef citations to date

Altmetric

Original Research

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

Faraz Razi1 Department of Paediatrics, Basingstoke and North Hampshire Hospital, Basingstoke, UKCorrespondence[email protected]

Adnaan Haq2 Department of Ophthalmology, Leicester General Hospital, Leicester, UK

Prabhu Tonne3 Department of Ophthalmology, Northampton General Hospital, Northampton, UK

Maharatnam Logendran3 Department of Ophthalmology, Northampton General Hospital, Northampton, UK

Pages 313-319 | Published online: 17 Feb 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Novartis PharmaceuticalsLucentis® ranibizumab (rbe)Novartis Pharmaceuticals2014 Available from: http://www.novartis.com.au/pi_pdf/luc.pdfAccessed January 21, 2016
Google Scholar
BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for Neovascular Age-Related Macular DegenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
International Council of OphthalmologyVisual Standards - Aspects and Ranges of Visual Loss with an Emphasis on Population SurveysInternational Council of Ophthalmology2002 Available from: http://www.icoph.org/downloads/visualstandardsreport.pdfAccessed January 21, 2016
Google Scholar
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
PubMed Web of Science ®Google Scholar
MunirajuRRamuJSivaprasadSThree-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degenerationOphthalmologica20132301273323635665
PubMed Web of Science ®Google Scholar
FrennessonCINilssonSEA three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outsActa Ophthalmol201492321622023452436
PubMed Web of Science ®Google Scholar
NICEBNF Lucentis® (Novartis)NICE Available from: http://www.evidence.nhs.uk/formulary/bnf/current/11-eye/118-miscellaneous-ophthalmic-preparations/1182-ocular-diagnostic-and-peri-operative-preparations-and-photodynamic-treatment/subfoveal-choroidal-neovascularisation/ranibizumab/lucentisAccessed January 21, 2016
Google Scholar
MitchellPKorobelnikJFLanzettaPRanibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBr J Ophthalmol201094121319443462
PubMed Web of Science ®Google Scholar
CarlsonNKurtzDClinical Procedures for Ocular Examination3rd edNew YorkMcGraw-Hill Education2003
Google Scholar
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
PubMed Web of Science ®Google Scholar
KodjikianLSouiedEHMimounGRanibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized TrialOphthalmology2013120112300230923916488
PubMed Web of Science ®Google Scholar
HolzFGAmoakuWDonateJSafety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
PubMed Web of Science ®Google Scholar
ShonaOGuptaBVemalaRSivaprasadSVisual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline visionClin Experiment Ophthalmol20113915821040311
PubMed Web of Science ®Google Scholar
WilliamsTABlythCPOutcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12Eye (Lond)201125121617162121921947
PubMed Web of Science ®Google Scholar
BandukwalaTMuniRHSchwartzCEngKTKertesPEffectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective reviewCan J Ophthalmol201045659059521135894
PubMed Web of Science ®Google Scholar
KaiserPKBrownDMZhangKRanibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR resultsAm J Ophthalmol2007144685085717949673
PubMed Web of Science ®Google Scholar
BoyerDSAntoszykANAwhCCSubgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degenerationOphthalmology2007114224625217270674
PubMed Web of Science ®Google Scholar
DadgostarHVenturaAAChungJYSharmaSKaiserPKEvaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degenerationOphthalmology200911691740174719643484
PubMed Web of Science ®Google Scholar
RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
PubMed Web of Science ®Google Scholar
GoodwinLDLeechNLUnderstanding Correlation: Factors That Affect the Size of rThe Journal of Experimental Education2006743249266
Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date